BiotechTube
CorriXR Therapeutics

CorriXR Therapeutics

Cambridge, United States· Est.
corrixr.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $32.2M

Overview

CorriXR Therapeutics is a private, pre-clinical stage biotech founded in 2020 and based in Cambridge, USA. The company is developing an in vivo CRISPR/Cas gene editing platform that targets the NRF2 pathway to reprogram the tumor microenvironment and re-sensitize solid tumors to standard-of-care treatments like chemotherapy and radiotherapy. Its initial focus is on head and neck squamous cell carcinoma (HNSCC), with a pipeline potentially applicable to over 30 squamous cell carcinoma indications. The company's approach combines a novel genetic target with a proven LNP delivery system administered locally to minimize off-target effects.

Oncology

Technology Platform

Proprietary in vivo CRISPR/Cas gene editing platform delivered via lipid nanoparticles (LNPs) for localized administration, designed to knock out the NRF2 pathway in solid tumors to overcome therapy resistance.

Funding History

2
Total raised:$32.2M
Series A$28M
Seed$4.2M

Opportunities

The high unmet need in recurrent and treatment-resistant solid tumors, particularly HNSCC, presents a significant market opportunity.
The platform's potential applicability to over 30 squamous cell carcinoma indications, including lung cancer, offers a substantial pipeline-in-a-product expansion strategy.
Positioning as a combination therapy that enhances standard-of-care could facilitate faster clinical adoption and integration into existing treatment paradigms.

Risk Factors

Major risks include the unproven long-term safety and efficacy of in vivo CRISPR editing in humans, potential for off-target effects, and navigating a novel regulatory pathway for a first-in-class modality.
The company also faces scientific risk in fully understanding the consequences of NRF2 knockout and competitive risk from other approaches targeting tumor resistance.

Competitive Landscape

CorriXR competes in the solid tumor resistance space, facing potential competition from small molecule inhibitors targeting the NRF2/KEAP1 pathway, other gene editing and gene therapy companies, and next-generation immunotherapies. Its differentiation lies in its precise CRISPR-mediated knockout and localized LNP delivery approach designed to re-sensitize tumors to a broad range of existing treatments.

More companies in United States →